The Department of Health and Social Care (DHSC) is working with industry on plans to minimise any medical supply disruption following a no-deal Brexit. This guidance summaries that approach. More information about it is in the letter to suppliers of medicines and medical products that come to the UK from or through the EU, Iceland, Lichtenstein or Norway.
Actions for businesses
DHSC is asking companies supplying the UK with medicines or medical products from or through the EU, Iceland, Liechtenstein or Norway to include the actions set out here in their Brexit planning. Companies can now determine for themselves the right mix of these actions for their specific situation, to most effectively ensure the continued flow of supplies.
Actions for companies supplying the UK with medicines from or through the EU, Iceland, Liechtenstein or Norway, should, as appropriate, include:
- securing capacity for rerouting freight away from Dover and Folkstone after 31 October 2019 – to avoid the disruption expected to follow a no-deal Brexit
- stockpiling a minimum of 6 weeks’ additional supply in the UK by 31 October – on top of your business-as-usual buffer stocks
- preparing logistics and supply chains to meet the new customs and border requirement for both importing and exporting – sometimes called ‘trader readiness’
- ensuring continued supply to the NHS as part of the contingency programme
- making alternative air freight plans for products with a short shelf-life or where production constraints mean stockpiling is not possible – for example, medical radioisotopes
- notifying DHSC of your company’s plans
DHSC will keep working with companies to ensure that plans will lead to the continuity of medical supplies after Brexit…